Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

In patients with hypercortisolism and inadequately controlled type 2 diabetes, mifepristone lowered HbA1c levels by about 1.5 ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting ...

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in ...

Stocks rose Monday, with oil prices declining, following a restrained response by Iran to U.S. attacks over the weekend.

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a ...